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DOI 10.1016/j.ccr.2011.01.038SUMMARYCD44 is an adhesion molecule expressed in cancer stem-like cells. Here, we show that a CD44 variant
(CD44v) interacts with xCT, a glutamate-cystine transporter, and controls the intracellular level of reduced
glutathione (GSH). Human gastrointestinal cancer cells with a high level of CD44 expression showed an
enhanced capacity for GSH synthesis and defense against reactive oxygen species (ROS). Ablation of
CD44 induced loss of xCT from the cell surface and suppressed tumor growth in a transgenic mouse model
of gastric cancer. It also induced activation of p38MAPK, a downstream target of ROS, and expression of the
gene for the cell cycle inhibitor p21CIP1/WAF1. These findings establish a function for CD44v in regulation of
ROS defense and tumor growth.INTRODUCTION
CD44, a major adhesion molecule for the extracellular matrix,
has been implicated in a wide variety of physiological processes,
including leukocyte homing and activation, wound healing, and
cell migration, as well as in tumor cell invasion and metastasis
(Gunthert et al., 1991; Nagano and Saya, 2004; Ponta et al.,
2003). It exists in numerous isoforms generated through alter-
native mRNA splicing. Whereas the standard CD44 isoformSignificance
Cancer stem cells (CSCs) manifest enhanced protection agains
chemo- or radiotherapy. Here, we show that expression of th
(CD44v), contributes to ROS defense by promoting the synthes
oxidant. CD44v interacts with and stabilizes xCT, a subunit of
uptake of cystine for GSH synthesis. Our findings reveal a ro
ROS in the tumor microenvironment. Moreover, they provide a
in cancer cells and sensitize them to currently available treatm(CD44s) is expressed predominantly in hematopoietic cells and
normal epithelial cell subsets, variant isoforms (CD44v) with
insertions in the membrane-proximal extracellular region are
abundant in epithelial-type carcinomas (Tanabe et al., 1993).
However, the functional relevance of CD44v in tumor cells
remains unclear.
CD44 has recently been identified as one of the cell surface
markers associated with cancer stem cells (CSCs) in several
types of tumor (Al-Hajj et al., 2003; Collins et al., 2005; Dalerbat reactive oxygen species (ROS), rendering them resistant to
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organized tumors; they are selectively capable of tumor initiation
and self-renewal and give rise to the bulk population of nontu-
morigenic cancer cells through differentiation. Furthermore, we
have recently shown that CD44v is heterogeneously expressed
in mouse gastric tumors, being highly abundant in proliferative
cells and slow-cycling stem-like cells, but not in cells harboring
mucin 5AC (MUC5AC) mRNA, a marker of gastric differentiation
(Ishimoto et al., 2010). These observations suggested that CD44
might play a role in tumor initiation and the maintenance of
cancer cells in addition to its more established functions in cell
adhesion and migration. However, function-based evidence to
support such a role for CD44 or its variant isoforms has been
lacking.
Oxidative stress occurs when production of reactive oxygen
species (ROS) exceeds the capacity of the cellular defense
system consisting of redox enzymes and other antioxidant mole-
cules. Like normal tissue stem cells, subsets of CSCs in some
tumors harbor only low levels of ROS and manifest enhanced
mechanisms for protection against ROS-mediated damage,
properties that may contribute to tumor resistance to chemo-
and radiotherapy (Diehn et al., 2009; Phillips et al., 2006).
Reduced glutathione (GSH) is a major cellular metabolite that
protects against oxidative and chemical injury and exhibits a
variety of other cytoprotective effects. High levels of GSH as
well as increased expression of antioxidant enzymes promote
cancer cell survival and resistance to anticancer agents (Tra-
chootham et al., 2009). System xc is a cystine-glutamate
exchange transporter composed of a light-chain subunit (xCT,
SLC7A11) and a heavy-chain subunit (CD98hc, SLC3A2).
Expression of xCT at the cell surface is essential for the uptake
of cystine required for intracellular GSH synthesis and is, thus,
an important determinant of intracellular redox balance (Lo
et al., 2008). Cells deficient in xCT or depleted of GSH have
recently been found to exhibit p38MAPK activation even at low
levels of oxidative stress (Chen et al., 2009; Sato et al., 2005),
indicating that xCT-mediated cystine transport for GSH
synthesis plays a key role in prevention of such stress signaling.
Furthermore, xCT has been implicated in the proliferation and
multidrug resistance of several types of cancer cells (Chen
et al., 2009; Huang et al., 2005; Lo et al., 2008). We carried out
this study to determine the function and mechanism of CD44v
in controlling redox status in cancer cells through the regulation
of xCT-mediated cystine transport.
RESULTS
CD44 Expression Correlates with ROS Defense, and
CD44 Ablation Activates ROS-p38MAPK Signaling
in Gastrointestinal Cancer Cells
CD44 is a cell surface marker for CSCs in various tumors, and
CSCs manifest low intracellular levels of ROS and enhanced
protection against ROS-mediated damage (Diehn et al., 2009).
Therefore, we hypothesized that CD44 expression is functionally
related to ROS defense in cancer cells. To investigate this
hypothesis we examined five human gastrointestinal cancer
cell lines that differ in CD44 expression status: three gastric
cancer lines (MKN28, AGS, KATOIII); and two colorectal cancer
lines (HT29, HCT116). These cells were exposed to 0.5 mM388 Cancer Cell 19, 387–400, March 15, 2011 ª2011 Elsevier Inc.hydrogen peroxide (H2O2) as an oxidative stressor for 20 min
and then examined by fluorescence microscopy after staining
with 20,70-dichlorofluorescein diacetate (DCFH-DA), a ROS-
sensitive fluorescent probe. The hydrolyzed compound DCFH
is oxidized to yield dichlorofluorescin (DCF), which is detectable
by fluorescence microscopy or flow cytometry (Behl et al., 1994;
Suematsu et al., 1992). In contrast to the cell lines (HCT116,
HT29, KATOIII) expressing a high level of CD44 (CD44high), those
negative for CD44 expression (CD44neg, MKN28) or expressing
CD44 at a low level (CD44low, AGS) showed pronounced
DCFH-DA staining (Figure 1A). Thus, this result suggested that
CD44high gastrointestinal cancer cells have a more efficient
ROS defense system than do CD44neg or CD44low cells.
To examine the functional relevance of CD44 expression to
ROS defense in CD44high cancer cells, we depleted these cell
lines of CD44 by RNA interference (RNAi) (Figure 1B). Flow cyto-
metric analysis revealed that HCT116 cells and HT29 cells
depleted of CD44 by transfection with a small interfering RNA
(siRNA) specific for CD44 mRNA showed a small increase in
DCFH-DA staining compared with those transfected with
a control siRNA (Figure 1C; see Figure S1A available online). In
KATO III cells, which have a higher basal ROS level than other
cell lines, CD44 depletion by transfection with a siRNA specific
for CD44 mRNA markedly increased DCFH-DA staining com-
pared with those transfected with a control siRNA (Figure S1A).
These results suggest that the increase of ROS levels by CD44
ablation depends on cell context and basal ROS levels.
To exclude the differences of cellular redox status and further
examine the role of CD44 on ROS defense ability, we exposed
the cells to H2O2. CD44-deficient HCT116 cells manifested
a markedly greater increase in DCFH-DA staining after exposure
to H2O2 than did those transfected with the control siRNA
(Figure 1C). Similar effects of CD44 ablation on H2O2-induced
DCF fluorescence were also observed in the other two CD44high
cell lines (HT29, KATOIII), although the efficiency of CD44 knock-
down differed between the two lines (Figure S1B). These results
indicated that CD44 expression contributes to ROS defense in
cancer cells.
To investigate further the potential role of CD44 in the cellular
response to oxidative stress, we examined the activation of
p38MAPK, a major target of ROS (Muller, 2009). Depletion of
CD44 by RNAi resulted in a marked increase in the phosphoryla-
tion (activation) level of p38MAPK in HCT116 cells exposed to
H2O2 (Figure 1D). The H2O2-induced p38
MAPK activation and
ROS accumulation in CD44-deficient HCT116 cells were
completely inhibited by treatment with N-acetylcysteine (NAC)
(Figures 1D and 1E). Thus, NAC treatment reversed the oxidative
stress phenotype of the CD44-depleted cells. These results sug-
gested that CD44 promotes ROSmetabolism in cancer cells and
thereby suppresses the activation of ROS-p38MAPK signaling.
CD44+ Gastric Tumor Cells Show a Low Level
of p38MAPK Phosphorylation In Vivo
To address the functional relevance of CD44 expression to
gastric tumorigenesis, we studied a transgenic mouse model
of gastric cancer, theK19-Wnt1/C2mE or Gan (gastric neoplasia)
mouse, in which both Wnt and prostaglandin E2 signaling path-
ways are activated in the gastric mucosa (Oshima et al., 2006).
These transgenic animals develop large, well-differentiated
Figure 1. CD44 Contributes to ROS Defense in Gastrointestinal Cancer Cells
(A) Cell lines incubated with 500 mMH2O2 for 20minwere stained with DCFH-DA (left, middle panels) andwith Hoechst 33342 (left, lower panels) and examined by
fluorescence microscopy. Cells not exposed to H2O2 were also analyzed with antibodies to CD44 and to Hoechst 33342 staining (left, upper panels). Scale bars,
100 mm. DCF fluorescence intensity (arbitrary units) was determined for >1000 cells in a representative experiment and is presented as mean ± SD values
(right panel).
(B) Flow cytometric analysis of CD44 expression on HCT116 cells transfected with control or CD44 siRNAs.
(C) HCT116 cells transfected with control or CD44 siRNAs were treated as in (A) and then stained with DCFH-DA, and subjected to flow cytometric analysis. RFI,
relative fluorescence intensity.
(D) HCT116 cells transfected with control or CD44 siRNAs were incubated in the absence or presence of 10 mMNAC for 5 min and then in the additional absence
or presence of 500 mMH2O2 for 20 min, lysed, and subjected to immunoblot analysis with indicated antibodies. The positions of bands corresponding to variant
(CD44v) and standard (CD44s) forms of CD44 are indicated. The fold increase in the intensity of the phospho-p38MAPK band relative to that in the leftmost lane is
also shown.
(E) HCT116 cells transfected with control or CD44 siRNAs were treated as in (D) and then stained with DCFH-DA and Hoechst 33342, and examined by fluores-
cence microscopy. Scale bars, 100 mm.
See also Figure S1.
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CD44 Promotes ROS Resistance in Cancer Cells(intestinal-type) gastric tumors and become moribund around
30–50 weeks of age (Oshima et al., 2006). We first examined
the expression of CD44 in the gastric tumors of 30-week-old
Gan mice. Reverse transcription (RT) and polymerase chain
reaction (PCR) analysis of normal stomach and gastric tumor
tissue revealed upregulation of CD44 mRNA in gastric tumors
(Figure 2A), indicating that an increase in CD44 gene expression
is associated with gastric tumorigenesis. Immunohistochemical
analysis also showed that CD44 expression was increased in
gastric tumors relative to that in the normal glandular stomach
but that its pattern of expression in the tumors was heteroge-
neous (Figure 2B). We further found that the phosphorylatedform of p38MAPK, which is normally expressed in the differenti-
ated gastric surface epithelial cells (Figure 2C, lower panel),
was preferentially detected in tumor cells that were negative
for CD44 staining (Figure 2C, upper panel). We recently showed
that CD44 expressed in the tumor cells of Gan mice consists
mostly of variant isoforms (CD44v8–10) containing amino acids
derived from exons 8–10 (Ishimoto et al., 2010). Furthermore,
RT-PCR analysis revealed that CD44v8–10 mRNA, rather than
CD44s mRNA, was the dominant form of CD44 mRNA present
in the human gastrointestinal cell lines AGS, HCT116, HT29,
and KATOIII (Figure S2). Therefore, we next examined the
relation between CD44v expression and phosphorylation ofCancer Cell 19, 387–400, March 15, 2011 ª2011 Elsevier Inc. 389
Figure 2. CD44 and Phospho-p38MAPK Expression in Gastric Tumors of Gan Mice
(A) RT-PCR analysis of expression of the CD44 gene and of transgenes in the stomach of wild-type (WT) or Gan mice at 30 weeks of age. Expression of the gene
for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was examined as a control.
(B) CD44 staining in the normal stomach of aWTmouse (lower image) and in a gastric tumor of a 30-week-old Ganmouse (left, upper images). The boxed region in
the left image is shown at higher magnification in the right image. Arrows and arrowheads indicate CD44+ and CD44 tumor cells, respectively. Col, columnar
epithelium; Sq, squamous epithelium. Scale bars, 1 mm (left, upper images) and 100 mm (lower image, and right, upper images).
(C) H&E and immunostaining for CD44 and phospho-p38MAPK in a gastric tumor of a 30-week-old Gan mouse (upper images). H&E and immunostaining for
phospho-p38MAPK in the normal stomach of a WT mouse (lower images). Arrows and arrowheads indicate inversely correlated expression of CD44 and
phospho-p38MAPK, respectively, in tumor cells. Scale bars, 100 mm.
(D) Immunofluorescence staining for CD44v and phospho-p38MAPK together with staining of nuclei with 40,6-diamidino-2-phenylindole (DAPI). Arrows and
arrowheads indicate inversely correlated expression of CD44v and phospho-p38MAPK, respectively, in tumor cells. Scale bars, 20 mm. Lower images show
CD44v, low-, and high-expressing cells at higher magnification of the boxed region in the upper image. Scale bars, 10 mm.
See also Figure S2.
(E) Dissociated tumor cells from Gan mice and glandular stomach cells from WT mice were stained with DCFH-DA and subjected to flow cytometric analysis.
(F) Dissociated tumor cells from Gan mice were subjected to flow cytometric analysis with antibodies to CD44v and DCFH-DA. RFI, relative fluorescence
intensity.
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fluorescence analysis revealed that the abundance of phospho-
p38MAPK was inversely correlated with CD44v expression within
a single tumorous gland (Figure 2D); CD44v cells expressed
high levels of phospho-p38MAPK, CD44v high-expressing cells
did not express phospho-p38MAPK, and CD44v low-expressing
cells expressed a moderate level of phospho-p38MAPK. Consis-
tent with our data obtained with the HCT116 cell line (Figure 1D),
p38MAPK activation was thus found to be suppressed in CD44v+
cells of mouse gastric tumors compared with that in CD44v
cells. Our observation that CD44 and phospho-p38MAPK expres-
sion appeared to be heterogeneous and inversely correlated
within individual tumorous glands of Gan mice suggested that
CD44+ tumor cells have an increased capacity for ROS defense.
To address this possibility we measured ROS level in tumor cells
isolated from Gan mouse by DCFH-DA. Gan mouse tumor cells390 Cancer Cell 19, 387–400, March 15, 2011 ª2011 Elsevier Inc.showed much higher DCFH-DA fluorescence compared with
normal mouse gastric cells (Figure 2E), indicating that Gan
mouse tumor contains a high level of ROS. We next investigated
whether CD44v+ tumor cells contain a lower level of ROS
compared with CD44v cells. DCFH-DA staining revealed that
CD44v+ tumor cells contain a much lower level of ROS than
CD44v cells (Figure 2F), suggesting that CD44 expression
status is associated with ROS defense ability of tumor cells.
Upregulation of Antioxidant Gene Expression
in CD44+ Tumor Cells
We next examined the expression of antioxidant genes in tumor
cells isolated from Gan mice by fluorescence-activated cell
sorting (FACS). Thus, lineage marker (Lin)-negative cells that
were CD44+ or CD44 were isolated from the gastric tumors
of 30-week-old Gan mice (Figure 3A) and subjected to cDNA
Figure 3. Upregulation of Antioxidant Gene Expression in CD44+ Gastric Tumor Cells Isolated from Gan Mice
(A) Dissociated tumor cells from Gan mice were subjected to flow cytometric analysis with antibodies to CD44. See also Figures S3A and S3B.
(B) Expression of the indicated antioxidant enzyme genes in CD44+ cells relative to that in CD44 cells isolated as in (A), as determined by cDNA microarray
analysis. Data are from a representative experiment.
(C) Antioxidant enzyme gene expression in CD44+ cells relative to that in CD44 cells isolated as in (A), as determined by quantitative RT-PCR analysis. Data were
normalized by the amount of GAPDH mRNA and are mean ± SD from three independent experiments. *p < 0.01.
(D) Antioxidant enzyme gene expression in HCT116 cells transfectedwith a control siRNA relative to that in cells transfectedwith a CD44 siRNA, as determined by
cDNA microarray analysis. Data are from a representative experiment. See also Figure S3C.
(E) Immunoblot analysis of CD44 and PRDX isoforms in HCT116 cells transfected with a control siRNA or CD44 siRNAs (#1 or #2) for the indicated times. ERK and
a-tubulin were similarly analyzed as loading controls.
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manifested increased expression of Wnt target genes but only
low levels of expression of marker genes for gastric differentia-
tion, including those forMUC5AC, gastric H+/K+-ATPase subunit
beta (Atp4b), gastric intrinsic factor (Gif), and pepsinogenC (Pgc)
(Figures S3A and S3B), suggesting that CD44+ tumor cells are
maintained in an undifferentiated state. The expression of
several key antioxidant genes, including those for glutathione
peroxidase (GPX) and peroxiredoxin (PRDX) isoforms, was found
to be increased in CD44+ tumor cells compared with that in
CD44 cells (Figure 3B), consistent with the notion that CD44+
tumor cells have an increased capacity for ROS defense. Quan-
titative RT-PCR analysis confirmed that the abundance of
mRNAs for GPX1 and GPX2, which are major H2O2-reducing
antioxidant enzymes in the gastrointestinal tract, as well as
that of mRNAs for PRDX1 and PRDX4 was significantly higher
in CD44+ tumor cells than in CD44 cells (Figure 3C). Similar toour observations for CD44+ gastric tumor cells, breast CSCs
have previously been found to express antioxidant enzyme
genes at increased levels and to show an enhanced ROS
defense ability compared with their nontumorigenic progeny
(Diehn et al., 2009).
We next examined whether depletion of CD44 might affect
antioxidant gene expression in cancer cells. Thus, HCT116 cells
were transfected with CD44 or control siRNAs and subjected to
cDNA microarray analysis or RT and real-time PCR analysis.
Although the CD44 siRNA was found to deplete the cells of
CD44 mRNA, the expression of antioxidant genes was largely
unaffected (Figures 3D; Figure S3C). We also examined the
abundance of PRDX isoforms in CD44-depleted HCT116 cells
by immunoblot analysis and found that CD44 depletion did not
affect the amounts of PRDX1, -2, -3, and -4 (Figure 3E). There-
fore, these results suggested that, although several antioxidant
enzyme genes are highly expressed in CD44+ cancer cellsCancer Cell 19, 387–400, March 15, 2011 ª2011 Elsevier Inc. 391
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cancer cells is largely independent of regulation of antioxidant
gene expression.
CD44v Regulates the Intracellular Level of GSH
On the basis of our observation that CD44 depletion did not
affect antioxidant gene or protein expression in cancer cells
(Figures 3D and 3E), we examinedwhether it might alter the intra-
cellular level of GSH in CD44high cancer cells. Depletion of CD44
was achieved with two different siRNAs that target different
sequences of CD44 mRNA (Figure S4A) and resulted in a
pronounced reduction in the intracellular GSH content of
HCT116 cells (Figure 4A), suggesting that CD44 contributes to
the regulation of the intracellular level of GSH. To examine
whether forced expression of CD44 affects intracellular GSH
content, we transiently transfected 293T cells (a transformed
human kidney cell line with a high transfection efficiency) with
an expression vector either for CD44s or for CD44v8–10, a major
variant isoform of CD44 in human gastrointestinal malignancies
(Figure S2) (Tanabe et al., 1993). The amount of GSH in cells
expressing CD44v was found to be significantly greater than
that in those expressing CD44s or in those transfected with the
empty vector (Figure 4B), suggesting that CD44v regulates intra-
cellular GSH content. Importantly, the increase of GSH content
achieved by CD44v8–10 expression was comparable to that
achieved by treatment with NAC, which is a precursor of GSH
and functions as an antioxidant (Figure 4B). All these findings
suggest that CD44v8–10 expression promotes GSH synthesis.
To further confirm this hypothesis, we stably transfected
MKN28 cells (CD44neg) with an expression vector either for
CD44s or for CD44v. The resulting CD44s- or CD44v-expressing
MKN28 cells (Figure S4B) were incubated for 24 hr with L-buthio-
nine-sulfoximine (BSO), which inhibits g-glutamylcysteinyl
synthase and thereby depletes intracellular GSH, and were
then allowed to recover for 24 hr in BSO-free medium. The
CD44v-expressing MKN28 cells, but not the CD44s-expressing
cells, were found to contain a significantly greater amount of
GSH at this time compared with cells transfected with the empty
vector (Figure 4C). Thus, this result suggested that CD44v, but
not CD44s, promotes GSH synthesis. Given that increased
GSH synthesis promotes resistance to anticancer agents that
induce ROS-mediated cytotoxicity (Trachootham et al., 2009),
we next investigated whether CD44v-dependent GSH synthesis
promotes the viability of cells exposed to H2O2 or to ROS-
inducing anticancer drugs such as cisplatin (CDDP) and doce-
taxel (DTX). We found that CD44v-expressing MKN28 cells
were more resistant to H2O2, CDDP, and DTX than were cells
stably transfected with the empty vector (Figure 4D). These
results suggested that promotion of GSH synthesis by CD44v
results in enhancement of cellular antioxidative capacity and
thereby promotes resistance to common chemotherapeutic
drugs.
Given that the availability of cysteine is rate limiting for GSH
synthesis (Ishii et al., 1987), we next investigated the effect of
CD44 depletion by RNAi on the amino acid content of HCT116
cells. This analysis revealed that CD44 depletion resulted in an
67%decrease in the amount of cysteine, whereas the amounts
of other amino acids including glutamate and glycine were not
similarly affected (Figure 4E). Given that the intracellular level392 Cancer Cell 19, 387–400, March 15, 2011 ª2011 Elsevier Inc.of cysteine is determined largely by the function of the xc
system, which exchanges extracellular cystine for intracellular
glutamate, with the cystine then being rapidly converted to
cysteine and utilized for GSH synthesis (Lo et al., 2008), we
hypothesized that CD44 might influence the function of this
transporter. To test this hypothesis we directly measured cystine
uptake in HCT116 cells by incubating the cells with 15N-labeled
L-cystine and then determining the intracellular contents of the
mass-labeled cysteine by CE-MS-based metabolome analysis
(Shintani et al., 2009). We found that CD44 ablation by RNAi
resulted in significant inhibition of cystine uptake in HCT116 cells
(Figure 4F; Table S1), suggesting that CD44 affects the function
of the cystine transporter.
CD44 Depletion Reduces the Cell Surface Expression
and Stability of xCT
The xCT subunit confers substrate specificity on the xc system,
allowing the cellular uptake of cystine in exchange for intracel-
lular glutamate, and is essential for cellular protection from
oxidative stress (Huang et al., 2005; Sato et al., 2005). To
examine whether the expression of xCT at the cell surface is
related to CD44 expression in cancer cells, we prepared amono-
clonal antibody that recognizes the extracellular domain of
human xCT and thenmeasured the amount of xCT at the surface
of the CD44high cancer cell lines HCT116, HT29, and KATOIII by
flow cytometry. The expression level of xCT at the surface of
these CD44high cancer cells was substantially higher than that
apparent for CD44neg (MKN28) cells (Figure 5A), suggesting
that cell surface expression of xCT might be related to CD44
expression. On the other hand we found that the amount of
xCT mRNA in these various cell lines was not correlated with
xCT protein expression at the cell surface (Figure S5A). We
also examined the possible effect of CD44 on the abundance
of xCT mRNA in HCT116 cells by RNAi. CD44 ablation resulted
in an increase in the amount of xCT mRNA, and this effect was
inhibited by NAC treatment (Figures S5B and S5C), indicating
that the increase in xCT mRNA abundance induced by CD44
depletion is due to increased intracellular accumulation of
ROS. The abundance of xCT mRNA was previously shown not
to correlate with the intracellular level of GSH in NCI-60 cancer
cells (Huang et al., 2005) but was found to be increased as
a result of cystine deprivation (Sasaki et al., 2002). Thus, our
results suggested that the amount of xCT mRNA is regulated
by the intracellular ROS level, whereas cell surface expression
of xCT might be regulated by CD44 expression status.
To examine the relevance of CD44 to the subcellular localiza-
tion of xCT, we performed immunocytofluorescence analysis by
confocal microscopy. Most xCT immunofluorescence at the
surface of HCT116 cells was found to colocalize with CD44
immunofluorescence, whereas RNAi-mediated CD44 ablation
reduced the amount of xCT at the plasmamembrane (Figure 5B).
Flow cytometry also revealed that CD44 ablation reduced the
amount of xCT at the cell surface without affecting the cell
surface expression of CD98hc in HCT116 cells (Figure 5C), sug-
gesting that CD44 regulates the subcellular localization of xCT,
but not that of CD98hc. We next investigated whether CD44
expression might affect the stability of xCT by establishing
HCT116 cells that stably express either a short hairpin RNA
(shRNA) specific for CD44 mRNA or a corresponding scrambled
Figure 4. CD44 Expression Correlates with the Intracellular Level of GSH
(A) GSH content of HCT116 cells transfected with CD44 siRNAs relative to that of those transfected with a control siRNA. Data are mean ± SD from three
independent experiments. *p < 0.01. See also Figure S4A.
(B) GSH content of HEK293T cells incubated with 1 mM NAC for 12 hr, expressing CD44v or CD44s relative to that of those transfected with the empty vector
(mock). Data are mean ± SD from three independent experiments. *p < 0.01.
(C)MKN28 cells stably expressing CD44v or CD44s, or those stably transfectedwith the empty vector (mock), were incubated with 500 mMBSO for 24 hr and then
allowed to recover in BSO-free medium for 24 hr. GSH content was analyzed as in (C). Data are mean ± SD from three independent experiments. *p < 0.01.
See also Figure S4B.
(D) MKN28 cells stably expressing CD44v, or those stably transfected with the empty vector (mock), were incubated for 72 hr with the indicated concentrations of
H2O2, CDDP, or DTX and then assayed for cell viability; data are expressed as treated/control cell ratio and are mean ± SD from three independent experiments.
The median inhibitory concentration (IC50) values are also shown.
(E) Amino acid contents of HCT116 cells transfected with the control siRNA or with CD44 siRNAs (#1 or #2). Data are expressed asmean ± SE from three separate
experiments. *p < 0.03 versus the value for cells transfected with the control siRNA. (F) Differences in 15N2-cystine uptake between HCT116 cells transfected with
CD44 siRNA and those transfected with the control siRNAs. Data are expressed as mean ± SE from five separate experiments. *p < 0.05. **p < 0.01 versus the
values for the cells transfected with the control siRNA.
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Figure 5. CD44 Regulates Cell Surface Expression of xCT, but Not that of CD98hc
(A) Flow cytometric analysis of cell surface xCT expression in HCT116, HT29, and KATOIII cells relative to that on MKN28 cells. Cells were stained with rat mono-
clonal antibodies to human xCT, which recognize the extracellular domain of xCT.
(B) Immunofluorescence analysis of xCT and CD44 in HCT116 cells transfected with control or CD44 siRNAs. Nuclei were also stained with DAPI.
Arrows indicate colocalization of xCT and CD44 at the cell surface; arrowheads indicate loss of surface expression of xCT in cells depleted of CD44.
Scale bars, 20 mm.
(C) Flow cytometric analysis of CD98hc, xCT, and CD44 expression at the surface of HCT116 cells transfected with control or CD44 siRNAs. Cells were stained
with antibodies to CD44 as well as with antibodies to CD98hc or to xCT.
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CD44 Promotes ROS Resistance in Cancer Cells(control) shRNA (Figure S5D). We measured the protein levels of
xCT by both immunoblot and FACS analyses. Treatment of the
cells with the protein synthesis inhibitor cycloheximide (CHX)
revealed that the levels of xCT in the cells expressing the CD44
shRNA were reduced significantly faster than those in the cells
expressing the control shRNA (Figures 5D; Figure S5E), suggest-
ing that CD44 expression enhances the stability of xCT protein.CD44v Interacts with and Stabilizes xCT
at the Plasma Membrane
Therefore, we hypothesized that CD44 and xCT interact at the
plasma membrane and that this molecular interaction stabilizes
the membrane localization of xCT and thereby promotes cystine
uptake in CD44high cancer cells. To test this hypothesis we
examined whether CD44 and xCT interact with each other by
immunoprecipitation analysis. Such analysis with antibodies to
CD44 revealed that both xCT and CD98hc indeed physically
interact with CD44 (Figure 5E). Furthermore, such analysis with
antibodies to xCT showed that xCT interacts preferentially with
130 kDa CD44v rather than with the 85 kDa CD44s isoform (Fig-
ure 5E). We recently found that CD44v (v6–10, v7–10, and v8–10)
was the predominant form of CD44 expressed in the gastric
tumors of Gan mice (Ishimoto et al., 2010). Thus, these observa-
tions suggested that CD44v may play a key role in resistance to
oxidative stress in gastrointestinal cancer cells and thereby
might promote tumor development.
To confirm that xCT preferentially interacts with CD44v, we
expressed recombinant CD44s or CD44v in 293T cells, which
contain only low levels of endogenous CD44, and performed
immunoprecipitation analysis with antibodies to xCT. Such anal-
ysis revealed that xCT specifically interacted with CD44v, not
with CD44s (Figure 5F). Together with our observation that
forced expression of CD44v, but not that of CD44s, increased
the intracellular GSH content in 293T cells (Figure 4B), these
results suggested that CD44v interacts with and stabilizes xCT
and thereby increases intracellular GSH content.
To further determinewhether variant region of CD44v is indeed
required for the interaction of CD44v and xCT, we generated
an expression plasmid encoding the S301A mutant of CD44v
(Figure S5F). Given that the v8–10 region of CD44v contains
consensus motifs for an N-linked glycosylation site (Asn-X-Ser/
Thr) (Dougherty et al., 1991), the CD44v S301A is considered
to be an N-linked glycosylation site mutant. The immunoprecip-
itation analysis revealed that the CD44v S301A failed to interact
with xCT (Figure 5G), suggesting that the v8–10 region of CD44 is(D) Left panels show immunoblot analysis of xCT and b-actin (loading control) in
(40 mg/ml) for the indicated times. In the right panels, mean values ±SD from three
corresponding value for time zero (0) are shown. See also Figure S5E.
(E) HCT116 cell lysates were subjected to immunoprecipitation (IP) with antibod
resulting precipitates, as well as the original cell lysates (input), were subject
(anti-CD44cyto).
(F) Lysates of HEK293T cells expressing CD44v or CD44s, or of those transfecte
antibodies to xCT or with control IgG, and the resulting precipitates, as well as
antibodies to xCT or to CD44 (anti-CD44cyto).
(G) Lysates of HEK293T cells expressing CD44v or CD44v (S301A), or those transf
or with control IgG, and the resulting precipitates, as well as the original cell lysat
CD44 (anti-CD44cyto).
(H) HEK293T cells expressing CD44v or CD44v (S301A), or those transfected with
expressed relative to the value for mock-transfected cells and are mean ± SD frorequired for the specific interaction between CD44v and xCT.
Furthermore, forced expression of the CD44v S301A failed to
increase basal GSH level in 293T cells (Figure 5H). These results
suggest that specific interaction of CD44v and xCT maintains
a high level of GSH in cancer cells.
To determine whether xCT contributes to the ROS defense
mechanism of CD44high (HCT116) cancer cells, we investigated
the effect of xCT depletion by RNAi (Figure S5G) on ROS-scav-
enging ability. Ablation of xCT resulted in a significant increase in
DCFH-DA staining in cells exposed to H2O2 (Figure S5H), as did
treatment with BSO (Figure S5I), suggesting that xCT-mediated
cystine uptake and consequent GSH synthesis are important for
theROS-scavenging ability of cancer cells. Furthermore,we found
that H2O2-induced activation of p38
MAPK was enhanced by xCT
depletion (Figure S5J), as it was by CD44 ablation (Figure 1D).
Thus, these results suggested that both CD44 and xCT are
required for suppression of ROS-induced p38MAPK activation.CD44 Ablation Reduces the Number of Proliferating
Tumor Progenitor Cells and Inhibits Gastric Tumor
Development in Gan Mice
To examine whether CD44 expression affects tumor cell expan-
sion during gastric tumorigenesis in vivo, we crossed Gan mice
with CD44 knockout (CD44/) mice, which show no overt
phenotype during development (Schmits et al., 1997), in order
to generate CD44/ Gan animals. Tumors were markedly
smaller in CD44/ Gan mice than in Gan mice at 30 weeks of
age and thereafter, whereas tumor size was similar in animals
of the two genotypes up to 20 weeks of age (Figures 6A and
6B), suggesting that CD44 is required for the maintenance of
tumor cell proliferation. Furthermore, hematoxylin and eosin
staining (H&E) revealed that CD44/ Gan mice only gave rise
to hyperplastic tumors (Figure 6B), suggesting that CD44
expression affects gastric tumor grade in Gan mice.
We next investigated themechanism underlying the difference
in tumor size between Gan mice and CD44/ Gan mice. The
proportion of proliferating tumor cells that incorporated bromo-
deoxyuridine (BrdU) was significantly smaller in CD44/ Gan
mice than in Gan mice (Figure 6C), indicating that the number
of proliferating progenitor cells was reduced in the CD44-defi-
cient hyperplastic tumors. In contrast the proportion of apoptotic
cells in tumors did not differ between mice of the two genotypes
(Figure 6D). Thus, these results indicated that CD44 contributes
to the proliferation of gastric tumor cells rather than to cell
survival in Gan mice.HCT116 cells stably expressing control or CD44 shRNAs and exposed to CHX
independent experiments for the xCT/b-actin band intensity ratio relative to the
ies to CD44 (IM7) or to xCT, or with control immunoglobulin G (IgG), and the
ed to immunoblot analysis with antibodies to xCT, to CD98hc, or to CD44
d with the empty vector (mock), were subjected to immunoprecipitation with
the original cell lysates (input), were subjected to immunoblot analysis with
ected with the empty vector (mock), were subjected to IPwith antibodies to xCT
es (input), were subjected to immunoblot analysis with antibodies to xCT or to
the empty vector (mock), were analyzed for intracellular GSH content. Data are
m three independent experiments. *p < 0.01. See also Figure S5F.
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Figure 6. Growth of Gastric Tumors in Gan Mice Is
Suppressed by CD44 Ablation
(A) Gastric mucosal thickness in Gan or CD44/ Gan
mice at the indicated ages relative to that in age-matched
wild-type (WT) mice. Data are mean ± SD for the indicated
number of animals. *p < 0.05 versus the corresponding
value for CD44/ Gan mice.
(B) Macroscopic images and H&E of gastric tumors of Gan
and CD44/ Gan mice at 30 weeks of age. Scale bars,
5 mm (upper panels) and 100 mm (lower panels).
(C) BrdU incorporation in gastric tumors of 30-week-old
Gan or CD44/ Gan mice (left panels). Scale bars,
100 mm. The BrdU-labeling index was determined as
mean ± SD values for five mice of each genotype (right
panel); *p < 0.02.
(D) Apoptosis index for gastric tumors of 30-week-old Gan
orCD44/Ganmice. Data are mean ± SD for four mice of
each genotype. NS, not significant.
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and p21CIP1/WAF1 Upregulation in Gastric Tumors
of Gan Mice
Given that sustained activation of p38MAPK is a characteristic
of cells with a high ROS level in vivo (Dolado et al., 2007), we
examined whether ablation of CD44 increases the abundance
of phospho-p38MAPK in gastric tumor cells. The region contain-
ing cells positive for phospho-p38MAPK was markedly extended
in hyperplastic tissue of CD44/ Gan mice compared with
that in tumors of Ganmice (Figure 7A). Furthermore, immunoblot
analysis revealed that the amount of phospho-p38MAPK was
greater in CD44-deficient hyperplastic tumors than in CD44+
tumors (Figures 7B and 7C) and that CD44v, rather than
CD44s, was preferentially expressed in the latter tumors (Fig-
ure 7B). We next investigated the relation between CD44v
expression and p38MAPK signaling in human gastric cancer.
The staining patterns of CD44v and phospho-p38MAPK were
inversely correlated in tumorous glands of human gastric adeno-
carcinoma (Figure S6). Together, these results suggested that
CD44v negatively regulates p38MAPK activity and that ablation
of CD44v induces tumor cells to adopt a more differentiated
and less proliferative state through activation of p38MAPK.
We next investigated whether the extension of the tumor
region positive for p38MAPK phosphorylation apparent in
CD44/ Gan mice might be due to the loss of the influence of
CD44 on the plasma membrane localization of xCT. Immunohis-
tochemical analysis revealed that genetic ablation of CD44 re-
sulted in a marked reduction in the amount of xCT at the cell
surface (Figure 7D), suggesting that the CD44-xCT axis might
regulate p38MAPK signaling through modulation of the intracel-
lular ROS level in gastric tumor cells.
To explore further the molecular mechanism underlying
p38MAPK-mediated tumor growth suppression, we examined
the expression of p21CIP1/WAF1, which is a major downstream
component of the pathway by which p38MAPK inhibits cell prolif-396 Cancer Cell 19, 387–400, March 15, 2011 ª2011 Elsevier Inc.eration (Han and Sun, 2007) and participates
in the differentiation of gastric epithelial cells
(Katz et al., 2005). Quantitative RT-PCR analysis
revealed that CD44 ablation resulted in a
significant increase both in the amount ofp21CIP1/WAF1 mRNA (Figure 7E) and in that of the mRNA for the
gastric differentiation marker MUC5AC (Figure 7F) in gastric
tumors of Gan mice. Together, these results suggested that
CD44 ablation triggers growth arrest in immature and prolifera-
tive tumor cells through activation of p38MAPK and upregulation
of p21CIP1/WAF1, resulting in the suppression of tumor progres-
sion through the induction of cell differentiation, in the Gan
mouse model.
The xCT Inhibitor Sulfasalazine Suppresses
CD44-Dependent Tumor Growth and Promotes
Activation of p38MAPK in Tumor Cells In Vivo
We next examined whether xCT contributes to CD44-dependent
tumor growth. HCT116 cells stably expressing CD44 shRNA
formed significantly smaller tumors in nude mice than did those
expressing a control shRNA (Figure 8A), suggesting that HCT116
cells form tumors in vivo in a CD44-dependent manner. Further-
more, immunoblot analysis revealed that RNAi-mediated CD44
knockdown markedly increased the phosphorylation of
p38MAPK in the tumor cells (Figure 8B), indicating that CD44-
dependent tumor growth is associated with the suppression of
p38MAPK-mediated signaling. Sulfasalazine is a well-character-
ized specific inhibitor of xCT-mediated cystine transport and
has been shown to inhibit the growth, invasion, and metastasis
of several types of cancer (Chen et al., 2009; Gout et al., 2001;
Lo et al., 2008). We found that intraperitoneal administration of
sulfasalazine inhibited the growth of tumors formed by HCT116
cells in nude mice (Figure 8C), suggesting that the function of
xCT plays a role in the expansion of CD44+ tumor cells in vivo.
Furthermore, immunohistochemical analysis revealed that sulfa-
salazine treatment stimulated the phosphorylation of p38MAPK in
HCT116 tumor cells in vivo compared with that apparent in mice
treated with saline (Figure 8D). Immunoblot analysis of tumor
lysates also showed that sulfasalazine treatment increased
p38MAPK activation (Figure 8D), as did RNAi-mediated CD44
Figure 7. CD44 Ablation in Gastric Tumors
Increases the Abundance of Phospho-
p38MAPK and Upregulates p21CIP1/WAF1
(A) Immunostaining of CD44 (a and b) and
phospho-p38MAPK (c and d) in gastric tumors
of 30-week-old Gan (a and c) or CD44/ Gan
(b and d) mice. Scale bars, 100 mm. See also
Figure S6.
(B) Immunoblot analysis of phospho-p38MAPK,
total p38MAPK, CD44, and ERK (loading control)
in lysates of gastric tumors from 30-week-old
Gan or CD44/ Gan mice.
(C) Amount of phospho-p38MAPK in gastric tumors
of 30-week-old CD44/ Gan mice relative to that
in those of Gan mice, as determined by immuno-
blot analysis. Data are mean ± SD for three mice
of each genotype. *p < 0.01.
(D) Immunostaining of xCT in gastric tumors of
30-week-old Gan or CD44/ Gan mice. Arrows
indicate expression of xCT at the plasma
membrane in tumors of Gan mice, whereas arrow-
heads indicate the loss of xCT expression at the
plasma membrane in tumors of CD44/ Gan
mice. Scale bars, 50 mm.
(E) Quantitative RT-PCR analysis of p21CIP1/WAF1
mRNA in tumors of 30-week-old CD44/ Gan
mice relative to that in those of Gan mice. Data were normalized by the amount of GAPDHmRNA and are mean ± SD for three mice of each genotype. *p < 0.02.
(F) Quantitative RT-PCR analysis of MUC5ACmRNA in tumors of 30-week-old CD44/Gan mice relative to that in those of Gan mice. Data were normalized by
the amount of GAPDH mRNA and are mean ± SD for three mice of each genotype. *p < 0.01.
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activity of xCT plays a role in the ability of CD44+ tumor cells to
evade oxidative stress and p38MAPK-mediated growth suppres-
sion in vivo.
Finally, we examined whether suppression of xCT function by
sulfasalazine might enhance the effect of the anticancer drug
CDDP on tumor growth. The antitumor effect of CDDP at a low
dose (2mg/kg) was significantly enhanced by treatment with sul-
fasalazine (Figure 8E), suggesting that sulfasalazine reduces the
ROS defense capacity of cancer cells and sensitizes them to
available chemotherapeutic drugs.
DISCUSSION
Our results revealed a function of CD44v that contributes to the
ROS resistance of gastrointestinal cancer cells. CD44+ gastric
tumor cells of Gan mice were shown to express antioxidant
genes at higher levels compared with CD44 tumor cells. We
found that CD44+ tumor cells expressedWnt target genes signif-
icantly higher than CD44 tumor cells (Figure S3A). Given that
Wnt signals have been shown to be activated in stem-like cancer
cells (Vermeulen et al., 2010), we assume that CD44+ fraction
contains more stem-like cells than CD44 fraction. The previous
report demonstrated that the CD44+ breast CSCsmanifest upre-
gulation of antioxidant genes (Diehn et al., 2009). Therefore, we
speculate that the differences in expression of antioxidant genes
in CD44+ and CD44 fractions are due to the proportion of stem-
like tumor cells included in each fraction. However, in the present
study we also show that CD44 ablation suppressed the
synthesis of the nonenzymatic antioxidant GSHwithout affecting
the level of antioxidant gene expression in cultured cancer cells,
indicating that CD44-mediated ROS resistance is largely inde-pendent of such antioxidant gene expression. Furthermore, we
found that CD44v interacts with and stabilizes the cystine trans-
porter subunit xCT and thereby regulates the intracellular level
of GSH in CD44+ cancer cells, resulting in suppression of
p38MAPK- and p21CIP1/WAF1-mediated growth inhibition. These
results indicate that ROS defense in CD44+ cancer stem-like
cells is supported by CD44v enhancement of GSH synthesis in
addition to high levels of antioxidant gene expression. We are
not able to rule out the possibility that CD44 directly or indirectly
controls the expression of antioxidant genes in CD44+ cancer
stem-like cells in vivo, thus with this issue requiring further
investigation.
Recent studies have indicated that increased levels of ROS
promote aging of hematopoietic stem cells (Ito et al., 2006)
and that, in Drosophila, high ROS levels sensitize hematopoietic
progenitors to the induction of differentiation (Owusu-Ansah and
Banerjee, 2009). On the other hand, CSCs aswell as normal stem
cells possess an enhanced ROS defense system (Diehn et al.,
2009; Phillips et al., 2006). Our results now show that CD44
expression correlates with ROS resistance in cancer cells as
a result of the enhancement of GSH synthesis by CD44. Thus,
expression of CD44 might serve as a functional marker for
CSCs with immature and ROS-resistant properties in various
tumor types.
CD44 is synthesized in multiple isoforms as a result of alterna-
tive mRNA splicing (Ponta et al., 2003). We and others have
previously shown that the expression of CD44v, but not that of
CD44s, is associated with progression of human gastrointestinal
malignancies (Tanabe et al., 1993). Furthermore, we have
recently shown that quiescent or slow-cycling gastric stem or
progenitor cells that reside in the normal mouse stomach and
undergo expansion during tumorigenesis express a high levelCancer Cell 19, 387–400, March 15, 2011 ª2011 Elsevier Inc. 397
Figure 8. Inhibition of xCT Function Increases p38MAPK Activity in Tumor Cells and Suppresses CD44-Dependent Tumor Growth In Vivo
(A) Macroscopic images of tumors formed in nude mice by HCT116 cells stably expressing control or CD44 shRNAs at 28 days after cell injection (top panel);
scale bar, 5 mm. The weight of tumors formed by HCT116 cells stably expressing the CD44 shRNA relative to that of those formed by the control cells was
also determined at 28 days after cell injection (bottom panel). Data are mean ± SD for five animals in each group. *p < 0.01.
(B) Lysates of tumors formed by HCT116 cells stably expressing control or CD44 shRNAs were subjected to immunoblot analysis with indicated antibodies
(right panel).
(C) Time course of the weight of tumors formed by HCT116 cells in nude mice treated with sulfasalazine (250 mg/kg) or saline. Data are mean ± SD for five mice
per group. *p < 0.01 versus the corresponding value for saline-treated animals.
(D) Immunostaining of phospho-p38MAPK in tumors formed by HCT116 cells in nude mice treated with sulfasalazine or saline (left panels); the boxed regions are
shown at higher magnification in the insets. Scale bars, 500 mm. Tumor lysates were also subjected to immunoblot analysis with indicated antibodies (right panel).
(E) The weight of tumors formed by HCT116 cells in nude mice treated with saline, CDDP (2 mg/kg), or CDDP (2 mg/kg) plus sulfasalazine (250 mg/kg) was
determined at 28 days after cell injection. Data are mean ± SD for five animals per group. *p < 0.01.
(F) Model for regulation of ROS-p38MAPK signaling by CD44v. CD44v maintains a high-level GSH by stabilizing the expression of xCT at the plasma membrane of
cancer cells. This action of CD44v results in suppression of ROS-p38MAPK signaling. HA, hyaluronic acid.
(G) Model for the role of the CD44v-xCT interaction in tumor development. CD44v and xCT interaction suppresses ROS-p38MAPK signaling in cancer cells by
upregulating intracellular GSH, thereby promoting tumor development.
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interacts with xCT and that CD44 ablation results in depletion of
intracellular GSH and loss of cell surface expression of xCT, with
the amount of CD98hc at the cell surface being apparently unaf-
fected. Furthermore, forced expression of CD44v8–10, but not
that of CD44s, accelerated the recovery of GSH content in
CD44 cancer cells after GSH depletion induced by BSO. These
observations suggest that CD44v-mediated stabilization of xCT
at the plasma membrane promotes ROS resistance and mainte-
nance of cancer cells.
xCT is a component of a plasma membrane transporter (the
xc system) that mediates the cellular uptake of extracellular
cystine in exchange for intracellular glutamate and thereby plays398 Cancer Cell 19, 387–400, March 15, 2011 ª2011 Elsevier Inc.a key role in GSH synthesis. The activity of xCT-mediated
cystine uptake in cancer cells is highly associated with cell
proliferation, chemoresistance, and tumor growth (Gout et al.,
2001; Lo et al., 2008). CD98hc is covalently linked to one of
several light chains, including LAT1, LAT2, y+LAT1, y+LAT2,
and ASC-1 in addition to xCT (Verrey et al., 2004), with the re-
sulting complexes functioning as amino acid transporters at
the plasma membrane. However, the precise mechanism by
which CD98hc selects its binding partner to constitute the
different types of amino acid transporter has remained
unknown. In the present study we showed that CD44v stabilizes
xCT expression at the plasma membrane, with the xc system
then mediating cystine uptake and promoting GSH synthesis.
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shown to interact with monocarboxylate transporter (MCT)-1
and MCT-4, which are responsible for the transport of lactate
in breast cancer cells (Slomiany et al., 2009). Therefore, it is
possible that different CD44v isoforms contribute to the stabili-
zation of several different types of transporter at the plasma
membrane.
We previously showed that CD44 expressed in invasive
cancer cells undergoes matrix metalloproteinase-dependent
cleavage, which promotes turnover of CD44-mediated cell-
matrix interaction and efficient invasion of extracellular matrix
(Nagano et al., 2004; Nagano and Saya, 2004). These previous
observations together with our present findings suggest that
CD44 contributes to both the matrix invasion and ROS defense
capabilities of cancer cells. It is possible that a switch between
these dual functions of CD44 is determined by its stable expres-
sion at the cell surface or its cleavage.
Oxidative stress has been implicated in activation of both
p38MAPK and p53-p21CIP1/WAF1 signaling and, consequently, in
cell-cycle arrest and senescence (Muller, 2009). Constitutive
activation of p38MAPK has been shown to negatively regulate
tumorigenesis (Bulavin et al., 2004; Dolado et al., 2007; Han
and Sun, 2007). Furthermore, p21CIP1/WAF1 is an important medi-
ator of the differentiation of gastrointestinal epithelial cells
(Katz et al., 2005; van de Wetering et al., 2002). Ablation of
CD44 in mice harboring a transgene for tumor necrosis factor-
a exacerbates chronic inflammatory arthritis as a result of exces-
sive p38MAPK activation, indicative of increased levels of ROS
(Hayer et al., 2005). Thus, expression of CD44 might be required
to support cell proliferation in an inflammatorymicroenvironment
characterized by increased oxidative stress. We have now
shown that CD44 ablation suppressed gastric tumor growth in
a mouse model of spontaneous tumorigenesis concomitant
with the upregulation of p38MAPK phosphorylation and
p21CIP1/WAF1 gene expression. Furthermore, treatment with the
specific xCT inhibitor sulfasalazine induced p38MAPK activation
and suppressed CD44-dependent tumor growth in an HCT116
xenograft model. Furthermore, the effect of the ROS-inducing
anticancer drug CDDP on CD44-dependent HCT116 tumor
growth was significantly enhanced by sulfasalazine treatment.
Together, these findings indicate that xCT-mediated suppres-
sion of ROS-p38MAPK signaling that negatively regulates the
tumorigenic and proliferative capacities of tumor cells plays
a role in the CD44-mediated expansion of tumor cells.
In conclusion our present data provide evidence that the
expression of CD44v and its association with xCT block the
ROS-induced stress signaling that results in growth arrest, cell
differentiation, and senescence, and thereby promote the prolif-
eration of cancer cells and the formation of lethal gastrointestinal
tumors (Figures 8F and 8G). Given that CD44-expressing CSCs
play a central role in resistance to cancer therapy, it has been
suggested that definitive treatment should target the CD44high
cell population in cancer. On the other hand, given that
CD44 appears to have numerous functions, further investigation
of other functions of this molecule in tumor growth and
maintenance is warranted. Our present study indicates that
CD44v-targeted therapy may impair the ROS defense ability of
gastrointestinal cancer stem-like cells and thereby sensitize
them to currently available cancer treatments.EXPERIMENTAL PROCEDURES
Transgenic Mice
K19-Wnt1/C2mE transgenic (Gan) mice were described previously (Oshima
et al., 2006). CD44/ mice were obtained from The Jackson Laboratory
(Bar Harbor, ME, USA). Ganmicewere crossedwithCD44/mice to generate
CD44/ Gan mice. Wild-type littermates of Gan mice were used as controls.
All animal experiments were performed in accordance with protocols
approved by the Ethics Committee of Keio University.
Statistical Analysis
Data are presented as mean ± SD and were analyzed with the unpaired
Student’s t test with the use of Excel 2007 (Microsoft, Redmond, WA, USA).
A p value of <0.05 was considered statistically significant.
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